Der 55-jährige Herr F. O. wird zur Lebertransplantation stationär aufgenommen. Eine Glukosestoffwechselstörung ist bei ihm nicht vorbekannt. Zwei Wochen nach der Transplantation erhält der Patient eine Immunsuppression mit Prednisolon 20 mg 1−0−0 und Tacrolimus 3 mg 1−0−1. Hierunter zeigen sich bei guter Leber- und Nierenfunktion die in Tab. 1 aufgeführten Blutzuckerwerte.
Literatur
Elena C, Chiara M, Angelica B, et al. Hyperglycemia and Diabetes Induced by Glucocorticoids in Nondiabetic and Diabetic Patients. Revision of Literature and Personal Considerations. Current pharmaceutical biotechnology 2018; 19: 1210–20. doi:https://doi.org/10.2174/1389201020666190102145305.
Perez A, Jansen-Chaparro S, Saigi I, Bernal-Lopez MR, Miñambres I, Gomez-Huelgas R. Glucocorticoid-induced hyperglycemia. Journal of diabetes 2014; 6: 9–20. doi:https://doi.org/10.1111/1753-0407.12090.
Radhakutty A, Burt MG. MANAGEMENT OF ENDOCRINE DISEASE. Critical review of the evidence underlying management of glucocorticoid-induced hyperglycaemia. European journal of endocrinology 2018; 179: R207–R218. doi:https://doi.org/10.1530/EJE-18-0315.
Liu X-x, Zhu X-m, Miao Q, Ye H-y, Zhang Z-y, Li Y-M. Hyperglycemia induced by glucocorticoids in nondiabetic patients. A meta-analysis. Annals of nutrition & metabolism 2014; 65: 324–32. doi:https://doi.org/10.1159/000365892.
Belle-van Meerkerk G, van de Graaf EA, Kwakkel-van Erp JM, et al. Diabetes before and after lung transplantation in patients with cystic fibrosis and other lung diseases. Diabetic medicine: a journal of the British Diabetic Association 2012; 29: e159–62. doi:https://doi.org/10.1111/j.1464-5491.2012.03676.x.
Bee YM, Tan HC, Tay TL, Kee TY, Goh SY, Kek PC. Incidence and risk factors for development of new-onset diabetes after kidney transplantation. Annals of the Academy of Medicine, Singapore 2011; 40: 160–67.
Anderson AL, Lewis DA, Steinke DT, Ranjan D, Smith KM, Clifford TM. Effects of hyperglycemia on the development of new-onset diabetes after liver transplantation. Progress in transplantation (Aliso Viejo, Calif.) 2009; 19: 298–303.
Depczynski B, Daly B, Campbell LV, Chisholm DJ, Keogh A. Predicting the occurrence of diabetes mellitus in recipients of heart transplants. Diabetic medicine: a journal of the British Diabetic Association 2000; 17: 15–19.
Healy SJ, Nagaraja HN, Alwan D, Dungan KM. Prevalence, predictors, and outcomes of steroid-induced hyperglycemia in hospitalized patients with hematologic malignancies. Endocrine 2017; 56: 90–97. doi:https://doi.org/10.1007/s12020-016-1220-2.
Ha Y, Lee K-H, Jung S, Lee S-W, Lee S-K, Park Y-B. Glucocorticoid-induced diabetes mellitus in patients with systemic lupus erythematosus treated with high-dose glucocorticoid therapy. Lupus 2011; 20: 1027–34. doi:https://doi.org/10.1177/0961203311402246.
Halden TAS, Kvitne KE, Midtvedt K, et al. Efficacy and Safety of Empagliflozin in Renal Transplant Recipients With Posttransplant Diabetes Mellitus. Diabetes care 2019. doi:https://doi.org/10.2337/dc19-0093.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Waldmann, E. So behandeln Sie den Steroiddiabetes richtig. MMW - Fortschritte der Medizin 161, 51–54 (2019). https://doi.org/10.1007/s15006-019-0513-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s15006-019-0513-9